Jochen Kammermeier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jochen Kammermeier has a total of 206 co-authors. Here are the top co-authors by number of shared publications:
- David C. Wilson
Child Life and Health, Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK
4 shared publications - Hans Holm Uhlig
Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK
4 shared publications - James John Ashton
Human Genetics and Genomic medicine University of Southampton Southampton UK
3 shared publications - Lissy de Ridder
Willem‐Alexander Children's Hospital/Leiden University Medical Center Leiden The Netherlands
3 shared publications - Peter Miles Irving
Department of Gastroenterology Guy's and St Thomas' NHS Foundation Trust London UK
3 shared publications - Simon P. L. Travis
Kennedy Institute of Rheumatology, Translational Gastroenterology & Liver Unit and NIHR Oxford Biomedical Research Centre, University of Oxford
3 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by BMJ in Frontline Gastroenterology
Best-practice recommendations for the transition care pathway for children and young people with moderate to severe ulcerative colitis: a modified Delphi panel with UK health care professionals
Objective: In the UK, the incidence of paediatric-onset ulcerative colitis (UC) is rising. UC is incurable, thus paediatric patients will require transfer to adult healthcare services. Effective transition is critical for continuity of good care while optimising treatment outcomes; however, transitional care currently varies across the UK. We aimed to develop UK consensus recommendations to facilitate optimal management of children and young people with moderately to severely active UC transitioning from paediatric to adult care. Design/Method: A modified Delphi, following the ACcurate COnsensus Reporting Document for Delphi research was conducted. Current clinical guidelines, treatment and transition pathways, pathway implementation and limitations were evaluated. A panel, comprising paediatric and adult gastroenterologists, plus paediatric gastroenterology specialist nurses, most with over 15 years of individual experience managing UC, participated in two anonymous online surveys and an online consensus conference to develop recommendations. Results: The Delphi study identified key areas for improvement, including the need for early preparation, tailored implementation and the integration of digital health resources. Consensus (agreement ≥75%) was achieved on the importance of structured transition pathways, developmentally appropriate guidance, joint clinics and the various healthcare professionals who should be involved in the transition process. The study highlighted potential barriers to the use of advanced therapies and the need for updated management guidelines. Conclusion: The consensus recommendations developed provide a framework for optimising the transition pathway for children and young people with UC moving to adult care, to improve outcomes and ensure continuity of care during this critical period.
- 1 October 2026
- Published by BMJ in Frontline Gastroenterology
Open AccessBest-practice recommendations for the transition care pathway for children and young people with moderate to severe ulcerative colitis: a modified Delphi panel with UK health care professionals
Objective: In the UK, the incidence of paediatric-onset ulcerative colitis (UC) is rising. UC is incurable, thus paediatric patients will require transfer to adult healthcare services. Effective transition is critical for continuity of good care while optimising treatment outcomes; however, transitional care currently varies across the UK. We aimed to develop UK consensus recommendations to facilitate optimal management of children and young people with moderately to severely active UC transitioning from paediatric to adult care. Design/Method: A modified Delphi, following the ACcurate COnsensus Reporting Document for Delphi research was conducted. Current clinical guidelines, treatment and transition pathways, pathway implementation and limitations were evaluated. A panel, comprising paediatric and adult gastroenterologists, plus paediatric gastroenterology specialist nurses, most with over 15 years of individual experience managing UC, participated in two anonymous online surveys and an online consensus conference to develop recommendations. Results: The Delphi study identified key areas for improvement, including the need for early preparation, tailored implementation and the integration of digital health resources. Consensus (agreement ≥75%) was achieved on the importance of structured transition pathways, developmentally appropriate guidance, joint clinics and the various healthcare professionals who should be involved in the transition process. The study highlighted potential barriers to the use of advanced therapies and the need for updated management guidelines. Conclusion: The consensus recommendations developed provide a framework for optimising the transition pathway for children and young people with UC moving to adult care, to improve outcomes and ensure continuity of care during this critical period.
- Open Access
Neutralising autoantibodies against IL-10 and HLA-DRB1*01:03 in paediatric patients with inflammatory bowel disease
Background: Interleukin-10 (IL-10) is an essential regulator of intestinal immune homeostasis. Neutralising autoantibodies against IL-10 (anti-IL-10) have been identified in children and also adult patients with IBD. Positivity for anti-IL-10 autoantibodies was associated with carriage of HLA-DRB1*01:03 allele. Objective: To determine the prevalence of anti-IL-10 in paediatric IBD and assess the associated clinical phenotype. Design: We conducted a cross-sectional multicentre study across paediatric IBD cohorts from four countries. Anti-IL-10 antibodies were investigated in serum and plasma from paediatric patients with IBD (mean age of IBD onset 11.2±3.8 years). IL-10-neutralisation capacity was confirmed by functional IL-10 reporter assay, competitive ELISA and cytokine release assay. Clinical data were analysed to evaluate disease phenotype and treatment outcomes, with comparison with matched controls. HLA-DRB1*01:03 analysis was performed. Results: Anti-IL-10 positivity was identified in 26/1045 paediatric patients with IBD (2.5%) (Crohn’s disease n=6, UC n=19, IBD unclassified n=1; IBD diagnosis age of 13±3 years). Anti-IL-10 autoantibodies were of the IgG class and amplified pro-inflammatory cytokine responses in vitro. Anti-IL-10-positive patients exhibited more severe disease compared with matched controls, including an increased prevalence of difficult-to-treat disease (23% vs 6%, p=0.03), higher rate of acute severe UC (26% vs 6%; p=0.038) and higher rates of colectomy (27% vs 6%, p=0.01). Eighty percent (16/20) of anti-IL-10-positive patients with available HLA data carried the HLA-DRB1*01:03 allele, compared with 1.5% in the anti-IL-10-negative group. Conclusion: Anti-IL-10 autoantibodies are present in a subgroup of paediatric patients with IBD and are associated with difficult-to-treat disease.
Open AccessNeutralising autoantibodies against IL-10 and HLA-DRB1*01:03 in paediatric patients with inflammatory bowel disease
Background: Interleukin-10 (IL-10) is an essential regulator of intestinal immune homeostasis. Neutralising autoantibodies against IL-10 (anti-IL-10) have been identified in children and also adult patients with IBD. Positivity for anti-IL-10 autoantibodies was associated with carriage of HLA-DRB1*01:03 allele. Objective: To determine the prevalence of anti-IL-10 in paediatric IBD and assess the associated clinical phenotype. Design: We conducted a cross-sectional multicentre study across paediatric IBD cohorts from four countries. Anti-IL-10 antibodies were investigated in serum and plasma from paediatric patients with IBD (mean age of IBD onset 11.2±3.8 years). IL-10-neutralisation capacity was confirmed by functional IL-10 reporter assay, competitive ELISA and cytokine release assay. Clinical data were analysed to evaluate disease phenotype and treatment outcomes, with comparison with matched controls. HLA-DRB1*01:03 analysis was performed. Results: Anti-IL-10 positivity was identified in 26/1045 paediatric patients with IBD (2.5%) (Crohn’s disease n=6, UC n=19, IBD unclassified n=1; IBD diagnosis age of 13±3 years). Anti-IL-10 autoantibodies were of the IgG class and amplified pro-inflammatory cytokine responses in vitro. Anti-IL-10-positive patients exhibited more severe disease compared with matched controls, including an increased prevalence of difficult-to-treat disease (23% vs 6%, p=0.03), higher rate of acute severe UC (26% vs 6%; p=0.038) and higher rates of colectomy (27% vs 6%, p=0.01). Eighty percent (16/20) of anti-IL-10-positive patients with available HLA data carried the HLA-DRB1*01:03 allele, compared with 1.5% in the anti-IL-10-negative group. Conclusion: Anti-IL-10 autoantibodies are present in a subgroup of paediatric patients with IBD and are associated with difficult-to-treat disease.
- 13 July 2024
- Published by BMJ in Frontline Gastroenterology
- Vol. 15 (5) , 387-394
Therapeutic options for children and young people with moderate-to-severe ulcerative colitis
There are ever-increasing therapeutic options for patients with ulcerative colitis (UC), but licensing and availability for children and young people are often years behind those aged >18 years. ‘Advanced therapies’, including biologics and small molecules, now target numerous different inflammatory pathways but continue to have a therapeutic ceiling with only 30–60% of patients responding to initial therapies, although with patients achieving mucosal healing having improved long-term outcomes. Within this review, we synthesise the paediatric evidence for the medicines, including anti-tumour necrosis factor, anti-integrin, anti-interleukin-12/23 monoclonal antibodies, alongside Janus kinase (JAK)-inhibitors and Sphingosine-1-phosphate inhibitors, used in moderate-to-severe UC, and extrapolate the adult literature where paediatric data are lacking. Finally, we look at the potential for optimal use and sequencing of these therapies when they are used in an empirical algorithm and consider some of the longer-term implications of loss of response.
- 13 July 2024
- Published by BMJ in Frontline Gastroenterology
- Vol. 15 (5) , 387-394
Therapeutic options for children and young people with moderate-to-severe ulcerative colitis
There are ever-increasing therapeutic options for patients with ulcerative colitis (UC), but licensing and availability for children and young people are often years behind those aged >18 years. ‘Advanced therapies’, including biologics and small molecules, now target numerous different inflammatory pathways but continue to have a therapeutic ceiling with only 30–60% of patients responding to initial therapies, although with patients achieving mucosal healing having improved long-term outcomes. Within this review, we synthesise the paediatric evidence for the medicines, including anti-tumour necrosis factor, anti-integrin, anti-interleukin-12/23 monoclonal antibodies, alongside Janus kinase (JAK)-inhibitors and Sphingosine-1-phosphate inhibitors, used in moderate-to-severe UC, and extrapolate the adult literature where paediatric data are lacking. Finally, we look at the potential for optimal use and sequencing of these therapies when they are used in an empirical algorithm and consider some of the longer-term implications of loss of response.
- 3 October 2023
- Published by Springer Nature in Nature Reviews Gastroenterology & Hepatology
- Vol. 20 (12) , 810-828
Precision medicine in monogenic inflammatory bowel disease: proposed mIBD REPORT standards
Owing to advances in genomics that enable differentiation of molecular aetiologies, patients with monogenic inflammatory bowel disease (mIBD) potentially have access to genotype-guided precision medicine. In this Expert Recommendation, we review the therapeutic research landscape of mIBD, the reported response to therapies, the medication-related risks and systematic bias in reporting. The mIBD field is characterized by the absence of randomized controlled trials and is dominated by retrospective observational data based on case series and case reports. More than 25 off-label therapeutics (including small-molecule inhibitors and biologics) as well as cellular therapies (including haematopoietic stem cell transplantation and gene therapy) have been reported. Heterogeneous reporting of outcomes impedes the generation of robust therapeutic evidence as the basis for clinical decision making in mIBD. We discuss therapeutic goals in mIBD and recommend standardized reporting (mIBD REPORT (monogenic Inflammatory Bowel Disease Report Extended Phenotype and Outcome of Treatments) standards) to stratify patients according to a genetic diagnosis and phenotype, to assess treatment effects and to record safety signals. Implementation of these pragmatic standards should help clinicians to assess the therapy responses of individual patients in clinical practice and improve comparability between observational retrospective studies and controlled prospective trials, supporting future meta-analysis.
- 3 October 2023
- Published by Springer Nature in Nature Reviews Gastroenterology & Hepatology
- Vol. 20 (12) , 810-828
Precision medicine in monogenic inflammatory bowel disease: proposed mIBD REPORT standards
Owing to advances in genomics that enable differentiation of molecular aetiologies, patients with monogenic inflammatory bowel disease (mIBD) potentially have access to genotype-guided precision medicine. In this Expert Recommendation, we review the therapeutic research landscape of mIBD, the reported response to therapies, the medication-related risks and systematic bias in reporting. The mIBD field is characterized by the absence of randomized controlled trials and is dominated by retrospective observational data based on case series and case reports. More than 25 off-label therapeutics (including small-molecule inhibitors and biologics) as well as cellular therapies (including haematopoietic stem cell transplantation and gene therapy) have been reported. Heterogeneous reporting of outcomes impedes the generation of robust therapeutic evidence as the basis for clinical decision making in mIBD. We discuss therapeutic goals in mIBD and recommend standardized reporting (mIBD REPORT (monogenic Inflammatory Bowel Disease Report Extended Phenotype and Outcome of Treatments) standards) to stratify patients according to a genetic diagnosis and phenotype, to assess treatment effects and to record safety signals. Implementation of these pragmatic standards should help clinicians to assess the therapy responses of individual patients in clinical practice and improve comparability between observational retrospective studies and controlled prospective trials, supporting future meta-analysis.
- 9 January 2023
- Published by Elsevier in The Lancet Gastroenterology & Hepatology
- Vol. 8 (3) , 271-286
Genomic diagnosis and care co-ordination for monogenic inflammatory bowel disease in children and adults: consensus guideline on behalf of the British Society of Gastroenterology and British Society of Paediatric Gastroenterology, Hepatology and Nutrition
- 9 January 2023
- Published by Elsevier in The Lancet Gastroenterology & Hepatology
- Vol. 8 (3) , 271-286
Genomic diagnosis and care co-ordination for monogenic inflammatory bowel disease in children and adults: consensus guideline on behalf of the British Society of Gastroenterology and British Society of Paediatric Gastroenterology, Hepatology and Nutrition
P310 Research priorities in digital technology for adolescents and young persons with inflammatory bowel disease
Introduction Evolution of digital technologies (DT) offers significant opportunities to transform inflammatory bowel disease (IBD) care. A James Lind Alliance (JLA) Priority Setting Partnership (PSP) aims to identify research priorities for DT in IBD. A survey was designed to identify unanswered questions or evidence uncertainties in the use of DT for adolescents and young persons with IBD. Methods PSP meetings were held with key stakeholders within a Steering Group (SG) consisting of: paediatric and adult gastroenterologists with an interest in adolescent and young person care from BSPGHAN and BSG respectively; IBD specialist nurses; representatives from Crohn’s in Childhood Research Association (CICRA) and Crohn’s and Colitis UK (CCUK) charities; patient and parent representatives. The survey was designed through an iterative process, considered complete when there was saturation of changes and approved by all stakeholders. A pilot survey with a feedback questionnaire resulted in additional minor changes to the structure and content and provided examples of research priorities to guide participants. Results A final survey consisting of three sections was approved by the SG. The first captures the respondent’s role and connection with IBD. The second invites them to submit questions about DT in two areas: DT to support their condition and improve IBD care, and DT to improve communication with the healthcare team. Open-ended questions are used to allow elaboration of answers with examples generated from the pilot survey to assist respondents articulate research questions. An optional last section captures demographic information not linked to responses in previous sections. Conclusions A survey (Figure 1) was developed and piloted as a first step to identify unanswered questions. Research priorities will be identified using the JLA methodology to galvanise DT research that may translate into improved disease outcomes and quality of life.
P310 Research priorities in digital technology for adolescents and young persons with inflammatory bowel disease
Introduction Evolution of digital technologies (DT) offers significant opportunities to transform inflammatory bowel disease (IBD) care. A James Lind Alliance (JLA) Priority Setting Partnership (PSP) aims to identify research priorities for DT in IBD. A survey was designed to identify unanswered questions or evidence uncertainties in the use of DT for adolescents and young persons with IBD. Methods PSP meetings were held with key stakeholders within a Steering Group (SG) consisting of: paediatric and adult gastroenterologists with an interest in adolescent and young person care from BSPGHAN and BSG respectively; IBD specialist nurses; representatives from Crohn’s in Childhood Research Association (CICRA) and Crohn’s and Colitis UK (CCUK) charities; patient and parent representatives. The survey was designed through an iterative process, considered complete when there was saturation of changes and approved by all stakeholders. A pilot survey with a feedback questionnaire resulted in additional minor changes to the structure and content and provided examples of research priorities to guide participants. Results A final survey consisting of three sections was approved by the SG. The first captures the respondent’s role and connection with IBD. The second invites them to submit questions about DT in two areas: DT to support their condition and improve IBD care, and DT to improve communication with the healthcare team. Open-ended questions are used to allow elaboration of answers with examples generated from the pilot survey to assist respondents articulate research questions. An optional last section captures demographic information not linked to responses in previous sections. Conclusions A survey (Figure 1) was developed and piloted as a first step to identify unanswered questions. Research priorities will be identified using the JLA methodology to galvanise DT research that may translate into improved disease outcomes and quality of life.
- Open Access
- 24 May 2022
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 16 (10) , 1609-1616
Thromboprophylaxis Use in Paediatric Inflammatory Bowel Disease: An International RAND Appropriateness Panel
Background and Aims: Thromboprophylaxis use in paediatric inflammatory bowel disease [IBD] is inconsistent. Current guidelines only support treating children with acute severe colitis with risk factors. We convened an international RAND panel to explore thromboprophylaxis in paediatric IBD inpatients in the context of new evidence. Methods: We convened a geographically diverse 14-person panel of paediatric gastroenterologists alongside supporting experts. An online survey was sent before an online meeting. Panellists were asked to rate the appropriateness of thromboprophylaxis in hospitalised paediatric IBD patients via 27 scenarios of varying ages, gender, and phenotype, with and without thrombotic risk factors. Anonymised results were presented at the meeting. A second modified survey was distributed to all panellists present at the meeting. Results from the second survey constitute the RAND panel results. The validated RAND disagreement index defined disagreement when ≥ 1. Results: The combined outcome of thromboprophylaxis being considered appropriate until discharge and inappropriate to withhold was seen in 20 of 27 scenarios, including: all patients with new-onset acute severe colitis; all flares of known ulcerative colitis, irrespective of risk factors except in pre-pubescent patients with limited disease and no risk factors; and all Crohn’s patients with risk factors. Disagreement was seen in five scenarios regarding Crohn’s without risk factors, where outcomes were already uncertain. Conclusions: RAND panels are an established method to assess expert opinion in areas of limited evidence. This work therefore constitutes neither a guideline nor a consensus; however, the findings suggest a need to re-evaluate the role of thromboprophylaxis in future guidelines.
- 24 May 2022
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 16 (10) , 1609-1616
Open AccessThromboprophylaxis Use in Paediatric Inflammatory Bowel Disease: An International RAND Appropriateness Panel
Background and Aims: Thromboprophylaxis use in paediatric inflammatory bowel disease [IBD] is inconsistent. Current guidelines only support treating children with acute severe colitis with risk factors. We convened an international RAND panel to explore thromboprophylaxis in paediatric IBD inpatients in the context of new evidence. Methods: We convened a geographically diverse 14-person panel of paediatric gastroenterologists alongside supporting experts. An online survey was sent before an online meeting. Panellists were asked to rate the appropriateness of thromboprophylaxis in hospitalised paediatric IBD patients via 27 scenarios of varying ages, gender, and phenotype, with and without thrombotic risk factors. Anonymised results were presented at the meeting. A second modified survey was distributed to all panellists present at the meeting. Results from the second survey constitute the RAND panel results. The validated RAND disagreement index defined disagreement when ≥ 1. Results: The combined outcome of thromboprophylaxis being considered appropriate until discharge and inappropriate to withhold was seen in 20 of 27 scenarios, including: all patients with new-onset acute severe colitis; all flares of known ulcerative colitis, irrespective of risk factors except in pre-pubescent patients with limited disease and no risk factors; and all Crohn’s patients with risk factors. Disagreement was seen in five scenarios regarding Crohn’s without risk factors, where outcomes were already uncertain. Conclusions: RAND panels are an established method to assess expert opinion in areas of limited evidence. This work therefore constitutes neither a guideline nor a consensus; however, the findings suggest a need to re-evaluate the role of thromboprophylaxis in future guidelines.
- 1 April 2022
- Published by BMJ
- Vol. 13 (Suppl 1) , A41-A43
IBD 9 Research priorities in digital technology for adolescents and young persons with Inflammatory Bowel Disease: a James Lind Alliance Priority Setting Partnership
Background Digital healthcare (DHC) is a rapidly expanding area of healthcare and offers significant opportunities to transform Inflammatory Bowel Disease (IBD) care. DHC cover a wide range of technologies, including and not exclusive to apps, podcasts, websites, social media and patient controlled electronic medical platforms. Application digital technology (DT) in clinical practice should be supported by research evidence. A Priority Setting Partnership (PSP) was set up in collaboration with the James Lind Alliance (JLA), a non-profit organisation, to prioritise research topics that young people with IBD, their carers, and their clinicians consider important for evidence-based implementation of DT in IBD. Aim To create a survey designed to identify the unanswered questions or evidence uncertainties in the use of DT for adolescents and young persons with IBD. Methods PSP meetings were attended by key stakeholders as a Steering Group (SG): paediatric and adult gastroenterologists with an interest in adolescent and young person care from BSPGHAN and BSG respectively, IBD clinical nurse specialists, representatives from the IBD charities CICRA and CCUK and patient and parent representatives. The survey was designed through an iterative process at a series of meetings. The survey was considered complete when there was saturation of changes and the approval by all stakeholders. Readability was assessed by the Flesch-Kincaid Reading Ease test (a measure of average sentence length average number of syllables per word) and Flesch-Kincaid Grade Level test on Microsoft Word. Methods of dissemination were discussed and agreed. Results The final survey consists of three sections. The first captures roles and connection of IBD to the individual completing the survey. The second invites participants to submit questions about DT in two areas: DT to support their condition and improve IBD care, and DT to improve communication with the healthcare team. Questions are open-ended to allow participants to elaborate on their answers. Due to the vast range of DT and potential questions, examples were provided to assist individuals with answering, including the example of a mobile app for recording symptoms and disease activity. The final section for demographic data is optional and will not be linked to responses in sections 1 or 2. Finally, participants are invited to be involved after the survey closes to help with further stages in the prioritisation process. The final survey is shown in figure 1. The Reading ease test score is 61 (good scores 60 to 70) and Flesch-kinaid grade level is 8.1 (optimal scores 7.0 to 8.0). The survey was approved by the patients within the SG. Conclusion A SG with wide representation for a PSP on DT in IBD was created. As a first step to identify unanswered questions or uncertainties, a readable survey was developed. Research priorities will be identified using the JLA methodology and these will galvanise research on DT to improve disease outcomes and quality of life. DIGITAL TECHNOLOGY FOR ADOLESCENTS AND YOUNG PERSONS WITH INFLAMMATORY BOWEL DISEASE A Priority Setting Partnership (PSP) in collaboration with the British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN), British Society of Gastroenterology (BSG) and the James Lind Alliance (JLA) WHO ARE WE?We are a group of patients, carers, healthcare professionals and researchers who are passionate about improving the care and quality of life of people living with inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn’s disease. Together, we are collaborating on a project called a Priority Setting Partnership (PSP), to identify the top 10 research priorities for digital technology in adolescents and young persons with IBD. WHAT ARE WE DOING?There are huge opportunities to transform IBD care with digital technologies, but we need to understand the impact that technologies will have and how to best use them. Digital technologies may include apps, podcasts, websites, social media and patient controlled electronic medical platforms. We are asking people up to and including the age of 25 who are affected by IBD; their families, carers and friends; health and social care professionals to help us identify the top 10 questions that need to be answered by research in this area. WHY DO WE NEED YOUR HELP?We would like to hear from you if you are: an adolescent or young person up to and including the age of 25 with IBD a parent, carer or friend supporting an adolescent or young person with IBD a health or social professional involved in the care of IBD patients Your views will ensure that we focus on the needs of adolescents and young persons living with the condition and guide future research. WHAT DO I HAVE TO DO?We are asking you to complete a short 10-minute survey. You don’t have to be an expert in technology to take part. Ask us questions about the use of digital technologies based on your experience of living with IBD or supporting someone with the condition. WHAT HAPPENS AFTER THE SURVEY?We will look at all the questions that have been asked in the survey and check that they align with this project. For the questions that have not been answered already by research, we would welcome you would help to put these into order of priority. Please leave your contact details at the end if you wish to be involved in this part. Finally, we will come up with a list of the top 10 research priorities which will be publicised to researchers and organisations that fund IBD research. WHAT WILL HAPPEN WITH MY INFORMATION?By taking part in this survey, you give us consent to use your anonymized answers and publish these in our project report. We take your privacy seriously so we will not be able to personally identify you. You may also leave contact details at the end if you would like to continue to help with this project (optional). Personal contact details will be kept confidential. THERE ARE THREE SECTIONS TO THIS SURVEY Section 1: This asks about who you are to help us understand your role and how you’re connected with IBD. Section 2: We would like you to ask questions about the use of digital technology in 2 broad areas. You may wish to focus on just one area or both: Questions about digital technologies to support your condition and have the potential to improve IBD care. These technologies help your healthcare team with making decisions about diagnosis, treatment, and clinical care. They may also help you self-manage IBD, promote healthier ways of living and monitor your progress. Examples include mobile apps for recording your symptoms and disease activity or provide information. Questions about the use of digital technologies to improve communication with your healthcare team. These technologies help to improve the two-way communication between you and the health professionals who look after you. Examples included instant messaging portals and video consultations that link you to healthcare teams. Section 3 (optional): This asks for additional background information about you to help us understand who you are and to ensure that we have captured a range of different experiences. These answers will not be linked to your responses in section 1 and 2. SECTION 1: ABOUT YOU It is important to know who you are, the person filling in the form, and how you are connected to IBD. Which of the following describes you best? □ I am an adolescent or young person with IBD □ I am a parent or have experience as a carer of an adolescent or young person with IBD □ I am a family member of an adolescent or young person with IBD □ I am a friend of an adolescent or young person with IBD □ I am a healthcare professional who looks after adolescents or young persons with IBD □ I am a member of an organisation or charity representing persons with IBD □ Other – please state…………….. SECTION 2: YOUR QUESTIONS Write down 3 questions that you would like to see answered about the use digital technology in inflammatory bowel disease. This can be in the form of a sentence or a question. You do not have to fill in all of the sections if you don’t want to. My first question/comment My second question/comment My third question/comment Please write down any other questions/concerns in the box below if you’d like to SECTION 3: ADDITIONAL INFORMATION ABOUT YOU (OPTIONAL) This optional but it is important to understand who is filling out the form to ensure that we have collected views from a range of people with varied experiences. 1. What is your age? □ Asian or Asian British □ Bangladeshi □ Chinese □ Indian □ Pakistani □ Any other Asian background, please describe………….. Black/African/Caribbean/Black British □ African □ Caribbean □ Any other Black/African/Caribbean background, please describe…… Mixed/Multiple ethnic groups □ Asian and White □ Black Caribbean and White □ Black African and White □ Any other mixed/Multiple ethnic background, please describe………. White □ English/Welsh/Scottish/Northern Irish/British □ Gypsy or Irish Traveller □ Irish □ Any other White background, please describe…….. Any other ethnic group □ Arab □ Any other ethnic group, please describe………… □ Prefer not to say 4. Where do you live? □ England □ Wales □ Scotland □ Northern Ireland □ I prefer not to say WOULD YOU LIKE TO HELP US WITH THE NEXT STEP?Once the survey has closed, we would like to get back in touch with the people who completed this survey for help with collating research questions into order of importance or urgency. If you would like to take part in this stage, please add your contact details below. Thank you for completing the survey. If you have any questions or would like any further information, please contact:………………………………
- 1 April 2022
- Published by BMJ
- Vol. 13 (Suppl 1) , A41-A43
IBD 9 Research priorities in digital technology for adolescents and young persons with Inflammatory Bowel Disease: a James Lind Alliance Priority Setting Partnership
Background Digital healthcare (DHC) is a rapidly expanding area of healthcare and offers significant opportunities to transform Inflammatory Bowel Disease (IBD) care. DHC cover a wide range of technologies, including and not exclusive to apps, podcasts, websites, social media and patient controlled electronic medical platforms. Application digital technology (DT) in clinical practice should be supported by research evidence. A Priority Setting Partnership (PSP) was set up in collaboration with the James Lind Alliance (JLA), a non-profit organisation, to prioritise research topics that young people with IBD, their carers, and their clinicians consider important for evidence-based implementation of DT in IBD. Aim To create a survey designed to identify the unanswered questions or evidence uncertainties in the use of DT for adolescents and young persons with IBD. Methods PSP meetings were attended by key stakeholders as a Steering Group (SG): paediatric and adult gastroenterologists with an interest in adolescent and young person care from BSPGHAN and BSG respectively, IBD clinical nurse specialists, representatives from the IBD charities CICRA and CCUK and patient and parent representatives. The survey was designed through an iterative process at a series of meetings. The survey was considered complete when there was saturation of changes and the approval by all stakeholders. Readability was assessed by the Flesch-Kincaid Reading Ease test (a measure of average sentence length average number of syllables per word) and Flesch-Kincaid Grade Level test on Microsoft Word. Methods of dissemination were discussed and agreed. Results The final survey consists of three sections. The first captures roles and connection of IBD to the individual completing the survey. The second invites participants to submit questions about DT in two areas: DT to support their condition and improve IBD care, and DT to improve communication with the healthcare team. Questions are open-ended to allow participants to elaborate on their answers. Due to the vast range of DT and potential questions, examples were provided to assist individuals with answering, including the example of a mobile app for recording symptoms and disease activity. The final section for demographic data is optional and will not be linked to responses in sections 1 or 2. Finally, participants are invited to be involved after the survey closes to help with further stages in the prioritisation process. The final survey is shown in figure 1. The Reading ease test score is 61 (good scores 60 to 70) and Flesch-kinaid grade level is 8.1 (optimal scores 7.0 to 8.0). The survey was approved by the patients within the SG. Conclusion A SG with wide representation for a PSP on DT in IBD was created. As a first step to identify unanswered questions or uncertainties, a readable survey was developed. Research priorities will be identified using the JLA methodology and these will galvanise research on DT to improve disease outcomes and quality of life. DIGITAL TECHNOLOGY FOR ADOLESCENTS AND YOUNG PERSONS WITH INFLAMMATORY BOWEL DISEASE A Priority Setting Partnership (PSP) in collaboration with the British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN), British Society of Gastroenterology (BSG) and the James Lind Alliance (JLA) WHO ARE WE?We are a group of patients, carers, healthcare professionals and researchers who are passionate about improving the care and quality of life of people living with inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn’s disease. Together, we are collaborating on a project called a Priority Setting Partnership (PSP), to identify the top 10 research priorities for digital technology in adolescents and young persons with IBD. WHAT ARE WE DOING?There are huge opportunities to transform IBD care with digital technologies, but we need to understand the impact that technologies will have and how to best use them. Digital technologies may include apps, podcasts, websites, social media and patient controlled electronic medical platforms. We are asking people up to and including the age of 25 who are affected by IBD; their families, carers and friends; health and social care professionals to help us identify the top 10 questions that need to be answered by research in this area. WHY DO WE NEED YOUR HELP?We would like to hear from you if you are: an adolescent or young person up to and including the age of 25 with IBD a parent, carer or friend supporting an adolescent or young person with IBD a health or social professional involved in the care of IBD patients Your views will ensure that we focus on the needs of adolescents and young persons living with the condition and guide future research. WHAT DO I HAVE TO DO?We are asking you to complete a short 10-minute survey. You don’t have to be an expert in technology to take part. Ask us questions about the use of digital technologies based on your experience of living with IBD or supporting someone with the condition. WHAT HAPPENS AFTER THE SURVEY?We will look at all the questions that have been asked in the survey and check that they align with this project. For the questions that have not been answered already by research, we would welcome you would help to put these into order of priority. Please leave your contact details at the end if you wish to be involved in this part. Finally, we will come up with a list of the top 10 research priorities which will be publicised to researchers and organisations that fund IBD research. WHAT WILL HAPPEN WITH MY INFORMATION?By taking part in this survey, you give us consent to use your anonymized answers and publish these in our project report. We take your privacy seriously so we will not be able to personally identify you. You may also leave contact details at the end if you would like to continue to help with this project (optional). Personal contact details will be kept confidential. THERE ARE THREE SECTIONS TO THIS SURVEY Section 1: This asks about who you are to help us understand your role and how you’re connected with IBD. Section 2: We would like you to ask questions about the use of digital technology in 2 broad areas. You may wish to focus on just one area or both: Questions about digital technologies to support your condition and have the potential to improve IBD care. These technologies help your healthcare team with making decisions about diagnosis, treatment, and clinical care. They may also help you self-manage IBD, promote healthier ways of living and monitor your progress. Examples include mobile apps for recording your symptoms and disease activity or provide information. Questions about the use of digital technologies to improve communication with your healthcare team. These technologies help to improve the two-way communication between you and the health professionals who look after you. Examples included instant messaging portals and video consultations that link you to healthcare teams. Section 3 (optional): This asks for additional background information about you to help us understand who you are and to ensure that we have captured a range of different experiences. These answers will not be linked to your responses in section 1 and 2. SECTION 1: ABOUT YOU It is important to know who you are, the person filling in the form, and how you are connected to IBD. Which of the following describes you best? □ I am an adolescent or young person with IBD □ I am a parent or have experience as a carer of an adolescent or young person with IBD □ I am a family member of an adolescent or young person with IBD □ I am a friend of an adolescent or young person with IBD □ I am a healthcare professional who looks after adolescents or young persons with IBD □ I am a member of an organisation or charity representing persons with IBD □ Other – please state…………….. SECTION 2: YOUR QUESTIONS Write down 3 questions that you would like to see answered about the use digital technology in inflammatory bowel disease. This can be in the form of a sentence or a question. You do not have to fill in all of the sections if you don’t want to. My first question/comment My second question/comment My third question/comment Please write down any other questions/concerns in the box below if you’d like to SECTION 3: ADDITIONAL INFORMATION ABOUT YOU (OPTIONAL) This optional but it is important to understand who is filling out the form to ensure that we have collected views from a range of people with varied experiences. 1. What is your age? □ Asian or Asian British □ Bangladeshi □ Chinese □ Indian □ Pakistani □ Any other Asian background, please describe………….. Black/African/Caribbean/Black British □ African □ Caribbean □ Any other Black/African/Caribbean background, please describe…… Mixed/Multiple ethnic groups □ Asian and White □ Black Caribbean and White □ Black African and White □ Any other mixed/Multiple ethnic background, please describe………. White □ English/Welsh/Scottish/Northern Irish/British □ Gypsy or Irish Traveller □ Irish □ Any other White background, please describe…….. Any other ethnic group □ Arab □ Any other ethnic group, please describe………… □ Prefer not to say 4. Where do you live? □ England □ Wales □ Scotland □ Northern Ireland □ I prefer not to say WOULD YOU LIKE TO HELP US WITH THE NEXT STEP?Once the survey has closed, we would like to get back in touch with the people who completed this survey for help with collating research questions into order of importance or urgency. If you would like to take part in this stage, please add your contact details below. Thank you for completing the survey. If you have any questions or would like any further information, please contact:………………………………
- 1 March 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (3) , 859-876
An Integrated Taxonomy for Monogenic Inflammatory Bowel Disease
- 1 March 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (3) , 859-876
An Integrated Taxonomy for Monogenic Inflammatory Bowel Disease
- Open Access
- 21 April 2021
- Published by BMJ
- Vol. 13 (1) , 77-81
Inflammatory bowel disease clinical service recovery during the COVID-19 pandemic
- 21 April 2021
- Published by BMJ
- Vol. 13 (1) , 77-81
Open AccessInflammatory bowel disease clinical service recovery during the COVID-19 pandemic